Guided Therapeutics (GTHP) Net Income towards Common Stockholders (2010 - 2025)
Guided Therapeutics (GTHP) reported Net Income towards Common Stockholders of -$1.2 million for Q4 2025, down 70.86% on a YoY basis from -$4.1 million in Q4 2024, and down 52.36% sequentially from -$785000.0 in Q3 2025.
Guided Therapeutics (GTHP) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$1.2 million in Q4 2025.
- For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 70.86% year-over-year to -$1.2 million; the trailing twelve-month figure through Dec 2025 stood at -$3.3 million (down 27.36% YoY), and the FY2025 full-year result was -$3.3 million, down 27.36% from the prior year.
- Net Income towards Common Stockholders declined to -$1.2 million in Q4 2025, from -$785000.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$51000.0 in Q3 2021 to a low of -$1.9 million in Q4 2022.
- A 5-year average of -$845700.0 and a median of -$771500.0 in 2024 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders jumped 82.87% in 2021 and sank 1966.67% in 2022, its largest moves.
- Tracing GTHP's Net Income towards Common Stockholders over 5 years: stood at -$509000.0 in 2021, then tumbled by 264.83% to -$1.9 million in 2022, then surged by 74.74% to -$469000.0 in 2023, then tumbled by 49.25% to -$700000.0 in 2024, then sank by 70.86% to -$1.2 million in 2025.
- Business Quant data shows GTHP's Net Income towards Common Stockholders at -$1.2 million in Q4 2025, -$785000.0 in Q3 2025, and -$856000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Guided Therapeutics | 20.78 Mn | 20.72 Mn | 458,000.00 | -1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.20 Mn |
| Sep 30, 2025 | -785,000.00 |
| Jun 30, 2025 | -856,000.00 |
| Mar 31, 2025 | -463,000.00 |
| Dec 31, 2024 | -700,000.00 |
| Sep 30, 2024 | -692,000.00 |
| Jun 30, 2024 | -758,000.00 |
| Mar 31, 2024 | -441,000.00 |
| Dec 31, 2023 | -469,000.00 |
| Sep 30, 2023 | -717,000.00 |
| Jun 30, 2023 | -1.60 Mn |
| Mar 31, 2023 | -969,000.00 |
| Dec 31, 2022 | -1.86 Mn |
| Sep 30, 2022 | -1.05 Mn |
| Jun 30, 2022 | -1.01 Mn |
| Mar 31, 2022 | -1.06 Mn |
| Dec 31, 2021 | -509,000.00 |
| Sep 30, 2021 | -51,000.00 |
| Jun 30, 2021 | -1.16 Mn |
| Mar 31, 2021 | -572,000.00 |